All News

The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma.

The FDA approved the quadruplet regimen on July 30 for induction and consolidation therapies in patients with newly diagnoses multiple myeloma who are eligible for autologous stem cell transplant.

New prevalence estimates of atrial fibrillation found that approximately 10.5 million US adults, or 5% of the population, have the condition.

The latest study findings suggest that acalabrutinib may be a safer option than ibrutinib for patients with chronic lymphocytic leukemia, offering a lower risk of serious cardiovascular and infection-related adverse events.

The rate of uninsurance in 2023 was 8.0%, a statistically insignificant change from the 7.9% uninsured rate in 2022.

Goals including addressing all of hunger and food insecurity, unmet needs for mental health services, and unstable housing or homelessness in people living with HIV are unlikely to meet their 2025 thresholds.

This interview accompanies the second podcast in our National Recovery Month series with Mandy Faubel, PhD, LCSW, UPMC Western Behavioral Health at Safe Harbor, and Rebekah Sedlock, DSW, LCSW, UPMC Insurance Services Division with Community Care.

An electronic version of the Symbol-Digit Modalities Test could enable people with multiple sclerosis (MS) to perform frequent remote cognitive assessments independently.

An update to the colonoscopy guidelines released by the American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy could have implications on how colonoscopies are measured in the future.

During the presidential debate, former President Donald Trump and Vice President Kamala Harris shared their differing visions for the future of the Affordable Care Act (ACA).

Adding bevacizumab to the combination therapy of carboplatin and paclitaxel significantly improved progression-free survival (PFS) in patients with epithelial ovarian cancer (EOC) but not overall survival (OS).

During ESMO Congress 2024, sessions will focus on hot topics in therapeutic areas, such as antibody-drug conjugates; the latest trial data; health policy; and advances in technology.

A new proof-of-concept method reliably engineered a hotspot mutation of SF3B1, a gene-splicing gene, into diverse cancer cell lines, outperforming other contemporary editing approaches.

Social frailty in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) does not directly impact anxiety or depression but influences these conditions indirectly through social support.

The European approval comes months after the FDA’s approval of the first-of-its-kind treatment for pulmonary arterial hypertension (PAH).

An AI segmentation system was able to identify changes in retinal segmented features based on optical coherence tomography (OCT) images.

Policy changes, such as banning spread pricing and promoting transparency, are necessary to realign the pharmacy benefit manager (PBM) market and ensure that health care resources benefit patients and providers rather than being diverted by middlemen, according to panelists at the Community Oncology Alliance Payer Exchange Summit.

Matthew Smeltzer, PhD, University of Memphis, shares insights into his team's quality-of-care initiative to identify and combat gaps in care for patients with early-stage non–small cell lung cancer (NSCLC).

A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood.

Speakers at the 2024 World Conference on Lung Cancer discussed the considerations that must go into designing and performing clinical trials in the early-stage lung cancer space, ranging from selecting an end point to empowering participants.

Breakthrough research identifies TIM3 as a key target in MAPK-activated pediatric gliomas, offering new hope for more effective immunotherapy treatments.

The need for improved collaboration between payers and providers is key to successfully implementing value-based care initiatives that address patient needs, ensure measurable outcomes, and overcome challenges, according to panelists at the Community Oncology Alliance Payer Exchange Summit.

The findings may help inform policy changes at the federal level aiming to address unfair and deceptive pharmacy benefit manager (PBM) practices.

Mammography facilities are now nationally required to inform patients about their breast density, which can affect cancer detection.

Drug use, participation in exchange sex, and depressive symptoms were all found to be associated with bacterial sexually transmitted infections (STIs) in sexual minority men living with HIV.

Biomarker testing is critical for determining optimal therapy early in the non–small lung cancer (NSCLC) treatment process, but research shows uneven insurance coverage of these tests and inconsistent uptake in cancer centers.

Luca Richeldi, MD, PhD, outlined crucial lessons from recent idiopathic pulmonary fibrosis (IPF) trial failures, advocating for adaptive trial designs, rigorous statistical methods, and a focus on patient-relevant outcomes to enhance future research.

Lung cancer is tied to tobacco smoking in the public consciousness, but a significant proportion of cases are driven by factors like indoor and outdoor air pollution or ancestral genetic variants.